Welcome to our dedicated page for Abbott Labs SEC filings (Ticker: ABT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Abbott Laboratories (NYSE: ABT), an Illinois-incorporated healthcare company whose common shares are listed on the New York Stock Exchange. Through these filings, investors can review official disclosures on Abbott’s operations, governance, financial reporting practices and material corporate events.
Abbott’s SEC filings include periodic reports and current reports on Form 8-K. Recent 8-K filings describe matters such as the entry into an Agreement and Plan of Merger with Exact Sciences Corporation, under which a wholly owned Abbott subsidiary will merge with Exact Sciences, with Exact Sciences surviving as a direct, wholly owned subsidiary of Abbott subject to customary closing conditions. Another 8-K details a notice of a blackout period for certain employee benefit plans due to administrative changes, including recordkeeper, trustee and custodian transitions, and outlines related trading restrictions for directors and executive officers. Additional 8-K disclosures cover corporate governance updates, such as amendments to Abbott’s by-laws to change the size of the board of directors and the appointment of a new director, as well as announcements of quarterly financial results and the company’s use of non-GAAP financial measures.
On Stock Titan, each new Abbott filing from the SEC’s EDGAR system can be viewed alongside AI-powered summaries that explain key points in clear language. These summaries help readers quickly understand topics like merger terms, benefit plan blackout periods, board changes, or how management presents adjusted financial metrics, without having to parse every technical detail. Users can also review exhibits referenced in the filings, such as merger agreements, notices to directors and officers, and amended by-laws, to see the underlying legal documents.
For those tracking insider-related information, governance changes or major transactions, Abbott’s SEC filings offer an authoritative record of the company’s regulatory disclosures, while AI-generated insights on this page aim to make those documents more accessible and easier to interpret.
ABBOTT LABORATORIES director John G. Stratton received a grant of 382 stock equivalent units as board compensation. The units were credited on the basis of a reference price of $102.67 per unit and are held in a stock equivalent unit account under a grantor trust established by the director.
The stock equivalent units are paid in cash, generally at age 65 or upon retirement from the board, and earn the same return as if the fees were invested in Abbott common shares, including a dividend reinvestment feature. Following this award, Stratton’s balance in the account totals 13,489 stock equivalent units. This is a non‑market, compensation-related acquisition rather than an open-market share purchase or sale.
ABBOTT LABORATORIES director Michael F. Roman received a grant of 367 stock equivalent units on Abbott shares as part of his director compensation. These units are credited to a stock equivalent unit account and are generally paid in cash at about age 65 or upon retirement from the board. Following this award, his balance totals 6,283 stock equivalent units, which earn the same return as if the underlying fees were invested in Abbott common shares, including units acquired through a dividend reinvestment feature.
Gonzalez Patricia Paola reported acquisition or exercise transactions in this Form 4 filing.
Abbott Laboratories director Patricia Paola Gonzalez received a grant of 321 Stock Equivalent Units as director compensation. These units were credited on March 31, 2026 at a reference value of $102.67 per unit and track the value of Abbott common shares.
The grant increased her balance to 5,558 Stock Equivalent Units, including amounts accumulated through a dividend reinvestment feature. The units are held in a grantor trust and are generally paid in cash around age 65 or upon retirement from the board, rather than being traded in the open market.
Alpern Robert J reported acquisition or exercise transactions in this Form 4 filing.
ABBOTT LABORATORIES director Robert J. Alpern received a grant of 76 stock equivalent units on March 31, 2026 as part of his director compensation. These units are valued at $102.67 per unit and track the return of Abbott common shares.
The units are credited to a stock equivalent unit account in a grantor trust established by the director and are generally paid out in cash at age 65 or upon retirement from the board. After this award and dividend reinvestment activity, his balance totals 10,544 stock equivalent units in this account.
Ahuja Nita reported acquisition or exercise transactions in this Form 4 filing.
ABBOTT LABORATORIES director Nita Ahuja received a grant of stock equivalent units as part of her board compensation. On this Form 4, she was awarded 102 stock equivalent units, each priced at $102.67, credited to a stock equivalent unit account.
The footnote explains these director fees are credited to the account and generally paid in cash at age 65 or upon retirement from the board, earning the same return as if invested in Abbott common shares. Following this grant, her reported balance in this account is 102 stock equivalent units.
Abbott Laboratories received an amended Schedule 13G/A from The Vanguard Group stating that, following an internal realignment, Vanguard and certain subsidiaries will report beneficial ownership separately. The filing lists Amount beneficially owned: 0 shares and Percent of class: 0% with an effective date shown as 03/13/2026.
ORVILLE JACOB A reported acquisition or exercise transactions in this Form 4 filing.
ABBOTT LABORATORIES Senior Vice President Orville Jacob A received a grant of 13,255 common shares as a restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 2-year term, with one-half vesting in any one year beginning on March 23, 2027.
Following this grant, he directly holds 50,493 common shares. The award includes the right to have shares withheld to cover tax obligations rather than paying taxes in cash.
ABBOTT LABORATORIES Senior Vice President Orville Jacob A filed an initial ownership report showing 37,238 common shares held directly. These shares represent a restricted stock unit award with a four-year term, vesting in equal annual installments starting on February 25, 2027, with the ability to have shares withheld for taxes.
The report follows Abbott’s acquisition of Exact Sciences Corporation, where each Exact common share was converted into the right to receive $105.00 in cash. Certain Exact restricted stock units were assumed by Abbott and converted into Abbott restricted stock units based on this merger consideration and Abbott’s 10-day average share price before closing.
Abbott Laboratories has completed its acquisition of Exact Sciences, making Exact a wholly owned subsidiary focused on cancer screening and diagnostics. Each Exact Sciences common share was converted into the right to receive $105.00 in cash at closing. Exact’s last trading day on Nasdaq was March 20, 2026. The deal adds leading products such as Cologuard, Oncotype DX, Oncodetect and Cancerguard, and expands Abbott’s presence in U.S. cancer screening and precision oncology diagnostics, which the company cites as a $60 billion market.